1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics.
1859 has raised $40.0M in total funding. The most recent round was Series A. The last funding was announced in February 2022.
1859's investors include Vertical Venture Partners, OMX Ventures, FusionX Ventures, Northpond Ventures.
1859 is headquartered in San Diego, United States.
1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics.
1859 is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"1859 — Funding & Investors." VCBacked, February 7, 2022, https://www.vcbacked.co/company/1859. Accessed October 16, 2026.
VCBacked. (2022). 1859 — Funding & Investors. Retrieved October 16, 2026, from https://www.vcbacked.co/company/1859
{{cite web |title=1859 — Funding & Investors |url=https://www.vcbacked.co/company/1859 |website=VCBacked |access-date=October 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated